Literature DB >> 28786433

Ammonia Levels and Hepatic Encephalopathy in Patients with Known Chronic Liver Disease.

Jacob Ninan1, Leonard Feldman2.   

Abstract

Ammonia is predominantly generated in the gut by intestinal bacteria and enzymes and detoxified primarily in the liver. Since the 1930s, ammonia has been identified as the principal culprit in hepatic encephalopathy (HE). Many physicians utilize serum ammonia to diagnose, assess severity, and determine the resolution of HE in patients with chronic liver disease (CLD) despite research showing that ammonia levels are unhelpful in all of these clinical circumstances. HE in patients with CLD is a clinical diagnosis of exclusion that should not be based on ammonia levels.
© 2017 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28786433     DOI: 10.12788/jhm.2794

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  12 in total

1.  Serum ammonia use: unnecessary, frequent and costly.

Authors:  Elizabeth Aby; Andrew P J Olson; Nicholas Lim
Journal:  Frontline Gastroenterol       Date:  2021-08-18

2.  The Role of Gut Microbiota in Mice With Bile Duct Ligation-Evoked Cholestatic Liver Disease-Related Cognitive Dysfunction.

Authors:  Bowen Yang; Tianning Sun; Yingle Chen; Hongbing Xiang; Jun Xiong; Shiting Bao
Journal:  Front Microbiol       Date:  2022-05-10       Impact factor: 6.064

Review 3.  Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends.

Authors:  Sasha Deutsch-Link; Andrew M Moon; Yue Jiang; A Sidney Barritt; Elliot B Tapper
Journal:  Clin Ther       Date:  2022-02-04       Impact factor: 3.637

4.  The effect of ammonia on canine polymorphonuclear cells.

Authors:  Craig R Breheny; Richard J Mellanby; Julie A Hamilton; Adam G Gow
Journal:  Vet Res Commun       Date:  2018-06-24       Impact factor: 2.459

5.  The critical role of hippocampal dopamine in the pathogenesis of hepatic encephalopathy.

Authors:  B Chen; Y Yang; S Li; X Zhu; Y Qi; F Hong
Journal:  Physiol Res       Date:  2021-01-14       Impact factor: 1.881

6.  An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy.

Authors:  Sayed Yossef; Frances Clark; Sarah S Bubeck; John Abernethy; Thomas Bayne; Kiran Krishnan; Aicacia Young
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-30       Impact factor: 2.629

Review 7.  Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.

Authors:  Daniela Campion; Ilaria Giovo; Paola Ponzo; Giorgio M Saracco; Federico Balzola; Carlo Alessandria
Journal:  World J Hepatol       Date:  2019-06-27

Review 8.  Advanced Organ-on-a-Chip Devices to Investigate Liver Multi-Organ Communication: Focus on Gut, Microbiota and Brain.

Authors:  Lucia Boeri; Luca Izzo; Lorenzo Sardelli; Marta Tunesi; Diego Albani; Carmen Giordano
Journal:  Bioengineering (Basel)       Date:  2019-09-28

9.  Prognosis of Patients with Sepsis and Non-Hepatic Hyperammonemia: A Cohort Study.

Authors:  Lina Zhao; Yanxia Gao; Shigong Guo; Xin Lu; Shiyuan Yu; Zengzheng Ge; Huadong Zhu; Yi Li
Journal:  Med Sci Monit       Date:  2020-12-29

10.  Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes.

Authors:  Rifaat Safadi; Robert S Rahimi; Dominique Thabut; Jasmohan S Bajaj; Kalyan Ram Bhamidimarri; Nikolaos Pyrsopoulos; Amy Potthoff; Stan Bukofzer; Laurene Wang; Khurram Jamil; Krishna R Devarakonda
Journal:  Clin Transl Sci       Date:  2022-03-03       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.